Low Rates of Soft-Tissue Complication with a Staged Protocol for Treatment of High-Energy Tongue-Type Calcaneus Fractures

Lawrence Henry Goodnough, MD; Eli W. Bunzel, MD; Malcolm DeBaun, MD; Stephen K. Benirschke, MD; Michael Githens, MD Harborview Medical Center, Seattle, WA, United States

Purpose: Tongue-type calcaneus fractures are reconstructive challenges often presenting with both soft-tissue compromise and severe articular injury. Early definitive intervention through a hostile soft-tissue envelope leads to wound problems. Thus, we have adopted a staged protocol consisting of early percutaneous reduction and temporary fixation. Anatomic joint reconstruction occurs when the soft-tissue envelope defervesces. We hypothesized that staged management of tongue-type calcaneus fractures would be associated with low rates of soft-tissue complications.

Methods: A single-center retrospective case series consisting of tongue-type calcaneus fractures treated with a staged protocol and minimum 3-month follow-up was performed. The primary outcome was reoperation for soft-tissue complication and a logistic regression was performed to assess for risk factors.

Results: 28 patients were identified. Mean Bohler's angle was -6.5° (± 24.6). 28 of 29 involved intra-articular extension, and 18 (66.7%) were Sanders III/IV. Soft-tissue compromise was present in 25 of 28 (89%). Definitive surgery occurred a median 16 days after injury (interquartile range 10.3-20 days). Soft-tissue–related reoperations occurred in 3 patients (10.7%). Type III open injuries (P = 0.03) were the only risk factor for the primary outcome.

Conclusion: In this series of tongue-type calcaneus fractures, initial displacement, soft-tissue injury, and degree of articular involvement were severe. Staged management with definitive reconstruction 2 to 3 weeks after injury was associated with a low rate of overall soft-tissue complications. High-grade open wounds were associated with subsequent wound-related complications, whereas initial displacement, lateral extensile approach, and time to definitive fixation were not.

	Median/range	IQR/SD	Risk factors for Se	6.4				
Age (years)	40.4 (14-83)	+/- 15.2	Risk Factor	OR OR	95% CI			
BMI (kg/m²)	26.6 (17.7- 41.8)	+/- 6.1	Age	1.1	95% C1 0.98-1.1	p-value 0.16	Α	- 600
Gender	41.0)		Male Sex	0.4	0.04-10.2	0.5	11120	100
Female	4/28	14%	Bohler's angle	0.99	0.95-1.04	0.8	1	
Male	24/28	86%	Smoker	1.8	0.2-39.5	0.63	(Allegaria)	23/17
Tobacco Use			Open fracture	7.0	0.7-81.8	0.1	CASES.	
Yes	18/28	64.3%	PF angle	1.0	0.98-1.1	0.27		
No	10/28	35.7%	Type III open	23	1.6-665	0.03	400000	
Sanders			Gastroc slide	0.2	0.01-1.8	0.03		
ш	9/28	33.3%	Lateral extensile	0.7	0.01-1.8	0.2	С	1
ш	14/28	51.9%					C	
IV	4/28	14.8%	Time to definitive	1.0	0.83-1.23	0.95	100	400
Open Fracture			A) Lateral vi	ew of	a displa	aced intra-	100	100
Closed	23/28	82.1%	articular tongu					ACCOUNT N
Open	5/28	17.9%	with threatene			a 4.0mm		
Soft Tissue Compromise			schanz pin			he dense	(0)(0)	
Absent	3/28	10.7%	subchondral b	one o	f the pos	terior facet	389	1
Present	25/28	89.3%	manipulates	the to	ngue fra	gment. D)	1000	N SSLAN WINES
Time	Median	IQR	smooth 7/64'	' Stei	nmann p	ins drilled	E	
Injury to Stage 1 (days)	0	0-1	across the	calcan	eocuboid	joint and		S 365
Injury to Stage 2 (days)	16	10.3-20	anchored in	to t	he cubo	oid resist		
	Number	%	displacement.	E) 16	days late	er definitive	P	15
Approach			treatment occi					-
Lateral extensile	16/28	57.1%	approach. F)			6 months		
Sinus	5/28	17.9%	demonstrated		erved h	eight and		7
Percutaneous	6/28	21.4%	articular congr	uity.				4000
External fixator	1/28	3.6%						

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.

Soft Tissue-Related Reop. 3/28 10.7%